Allergan Inc (AGN)

AGN (NYSE:Drugs)
$209.09
pos +0.00
+0.00%
Today's Range: 208.51 - 212.07 | AGN Avg Daily Volume: 2,764,400
Last Update: 11/21/14 - 4:00 PM EST
Volume: 0
YTD Performance: 88.23%
Open: $0.00
Previous Close: $210.20
52 Week Range: $94.98 - $214.20
Oustanding Shares: 297,898,630
Market Cap: 62,618,292,026
6-Month Chart
TheStreet Ratings Grade for AGN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 9 6 7
Moderate Buy 0 0 0 0
Hold 8 4 6 5
Moderate Sell 0 0 0 0
Strong Sell 0 1 1 1
Mean Rec. 2.14 1.86 2.23 2.08
Latest Dividend: 0.05
Latest Dividend Yield: 0.10%
Dividend Ex-Date: 11/18/14
Price Earnings Ratio: 49.11
Price Earnings Comparisons:
AGN Sector Avg. S&P 500
49.11 49.30 25.70
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
27.20% 111.67% 157.63%
GROWTH 12 Mo 3 Yr CAGR
Revenue 8.50 0.28 0.09
Net Income -10.30 258.69 5.26
EPS -9.80 0.00 0.00
Earnings for AGN:
EBITDA 2.07B
Revenue 6.30B
Average Earnings Estimates
Qtr (12/14) Qtr (03/15) FY (12/14) FY (12/15)
Average Estimate $1.81 $1.81 $6.29 $8.58
Number of Analysts 10 2 13 13
High Estimate $1.83 $1.84 $6.30 $8.65
Low Estimate $1.76 $1.77 $6.23 $8.38
Prior Year $1.35 $1.18 $4.77 $6.29
Growth Rate (Year over Year) 34.30% 52.97% 31.77% 36.51%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Jim Cramer

 | Nov 18, 2014 | 4:04 PM EST

In this market, negativity is rarely being rewarded.

By

Jim Cramer

 | Nov 17, 2014 | 4:16 PM EST

The U.S. markets and economy are unique.

By

Brian Sozzi

 | Nov 17, 2014 | 1:00 PM EST

What this year-end flurry of deals highlights.

By

Jim Cramer

 | Nov 17, 2014 | 11:35 AM EST

The CEO of Allergan has created value for shareholders.

By

Antonia Oprita

 | Nov 17, 2014 | 5:30 AM EST

Japan falls back into a deep recession.

By

Jim Cramer

 | Nov 17, 2014 | 4:33 AM EST

There's a powerful collection of "what's working."

By

Jim Cramer

 | Oct 30, 2014 | 12:19 PM EDT

Remember these franchises and who captains them.

By

Doug Kass

 | Oct 27, 2014 | 7:51 AM EDT
Where it began.
By

Kate Stalter

 | Oct 17, 2014 | 1:00 PM EDT

Hospitals, biotechs and drug makers continue to hold their own.

By

Kate Stalter

 | Oct 17, 2014 | 1:00 PM EDT

Hospitals, biotechs and drug makers are continuing to hold their own during this downturn.

Well this is confusing...our models were calling for a run to 2072 before a bearish revers...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.